Skip to main content

Market Overview

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

Share:
Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy
  • Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma.
  • The data will be presented at the upcoming European Hematology Association (EHA) Virtual Congress 2021.
  • No severe/life-threatening treatment-related adverse events nor evidence of Graft-versus-Host disease were reported from the completed first dose-level (DL1) cohort of the trial.
  • Initial results at a low dose of 30x106 cells per infusion showed preliminary signs of clinical activity, including a confirmed partial response.
  • CYAD-211 is an investigational, non-gene edited allogeneic CAR T candidate engineered to co-express a single hairpin RNA (shRNA) and a BCMA-targeting chimeric antigen receptor.
  • Price Action: CYAD shares are trading 21.9% higher at $6.47 during the premarket session on the last check Thursday.
 

Related Articles (CYAD)

View Comments and Join the Discussion!

Posted-In: Briefs multiple myeloma Phase 1 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com